智通财经7月30日电，深交所公告，港股通标的证券名单发生调整并自2025年07月30日起生效，调出东 阳光长江药业。 ...

Investment Rating - The report maintains a "Positive" investment rating for the express delivery industry [8]. Core Insights - The express delivery industry is expected to experience a "de-involution" phase, with significant policy catalysts anticipated in the upcoming months. The transition from the off-peak to peak season is expected to enhance the pricing power of express companies [2][11]. - The pricing increase duration is projected to be between 2 to 4 months, with a price increase of 0.06 to 0.30 yuan per ticket expected during the peak season. The profit per ticket is anticipated to improve by 0.01 to 0.10 yuan in Q4 [2][11]. - The average profit elasticity for e-commerce express delivery is expected to reach double digits, with second-tier express companies showing even more significant profit elasticity [2][11]. Summary by Sections Event Description - The report discusses the recent meeting of the State Post Bureau, which emphasized the need to combat "involution" in the express delivery sector. It addresses three main questions: the timing and sustainability of the current "de-involution," the profit elasticity for core enterprises, and the tools available for this process [6]. Pricing Dynamics - The report analyzes historical pricing trends, indicating that the current "de-involution" phase may be catalyzed by policy changes, with pricing increases expected to last longer than in 2024 but shorter than in 2021. The report references past data to illustrate potential outcomes [11][20]. Profit Elasticity - The report provides a detailed analysis of profit elasticity for major express companies, projecting that if the industry begins to raise prices in August and continues until December, the net profit for companies like Zhongtong, Yunda, and Shentong could reach 95.8 billion, 40.6 billion, and 17.4 billion yuan respectively, with corresponding profit elasticities of 6.5%, 12.7%, and 27.9% [20][21]. Tools for "De-involution" - The report identifies two main strategies for achieving "de-involution": regulatory measures to curb price wars and encouraging mergers and acquisitions among leading companies to optimize competition. The acquisition of Danbird Logistics by Shentong Express is highlighted as a significant step towards improving market dynamics [25][26]. Investment Recommendations - The report suggests actively seizing opportunities presented by the "de-involution" phase, recommending companies such as YTO Express, Shentong Express, Zhongtong Express, Jitu Express, and Yunda [21].

Investment Rating - The report maintains a "Positive" investment rating for the express delivery industry [1] Core Insights - The express delivery industry is experiencing a trend of "anti-involution," leading to a revaluation of its value [3] - The report emphasizes the importance of regulatory actions in stabilizing the industry and improving profitability [3] - Short-term price improvements are expected, with potential for further increases during peak seasons [3] Summary by Sections 1. Review of 2021's "Anti-Involution" - In 2021, the express delivery industry saw a significant policy push to protect courier rights, leading to price increases and improved profitability [3][19] - The average price per ticket for the "Tongda" system increased by approximately 0.6 yuan from the low point in August 2021 to January 2022 [3] - By Q4 2021, YTO Express reported a net profit of 1.15 billion yuan, a year-on-year increase of 202% [3] 2. Current Industry Dynamics - After 2023, the industry has re-entered a phase of price competition due to increased capacity and market share strategies, leading to profitability nearing historical lows [3][39] - The National Postal Administration has clearly opposed "involution-style" competition, indicating a regulatory environment similar to that of 2021 [3][65] - The report suggests monitoring regulatory developments in key production areas like Yiwu and Guangdong for potential price adjustments [3] 3. Short-term and Long-term Outlook - Short-term price improvements are anticipated, particularly in traditionally low-price cities, with potential for broader price increases in peak seasons [3][69] - The report forecasts a shift from price wars to value competition, which could enhance long-term profitability for leading express companies [3][69] - Investment recommendations include focusing on A-shares such as Shentong Express, YTO Express, and Yunda Express, as well as H-shares like Jitu Express and ZTO Express [3] 4. Financial Performance Metrics - In Q1 2025, the net profit per ticket for major companies like Zhongtong, YTO, Yunda, and Shentong fell close to or below historical lows [50] - The report highlights significant cash flow pressures, with some companies experiencing cash flow performance worse than the bottom of 2021 [50] - The report provides elasticity calculations indicating that price increases could significantly enhance profitability for express companies [70]

Summary of Conference Call Notes Industry Overview - **Aviation Industry**: The aviation sector has experienced significant losses since 2020, totaling nearly 500 billion. This has led to a drastic decline in supply, with the compound annual growth rate dropping from 12% to less than 3% [1][4]. - **Express Delivery Industry**: The express delivery sector has seen an escalation in price wars since 2024, with both single ticket prices and profitability entering a downward trend [3][8]. Key Insights and Arguments Aviation Industry - **Price Dynamics**: Airline ticket prices are increasingly reflecting supply and demand realities rather than expectations. As of May 2024, ticket prices have shown signs of recovery, primarily driven by supply-demand relationships [1][2]. - **Demand Recovery**: Although demand has rebounded quickly, business travel remains weak, with a 10% month-on-month decline in June due to factors like the alcohol ban [1][4]. - **Profitability Outlook**: The aviation sector is expected to return to profitability in 2024 after five years of significant losses. Current expectations for profitability are low, indicating limited risk in buying airline stocks with a high probability of upside [1][5][6]. - **Recommended Stocks**: High-elasticity airline stocks are recommended, including major Hong Kong carriers (Air China, China Eastern, China Southern) and A-share companies (HNA, Spring Airlines, and Juneyao Airlines) [1][5]. Express Delivery Industry - **Regulatory Environment**: The National Postal Administration has initiated anti-involution measures, with expectations for specific details to be implemented soon. Key production areas like Yiwu and Guangdong are already taking steps to stabilize prices [1][7]. - **Market Dynamics**: The express delivery market is currently facing intense competition, with a significant impact on franchise operations. The first quarter of 2024 showed mixed results, and the second quarter is expected to see a decline across the board [3][8]. - **Recommended Companies**: Leading express delivery companies such as YTO and ZTO are recommended due to their ability to regain market share amid price wars. Companies like Jitu and Shentong are also highlighted for their potential to improve governance and performance [3][10]. Additional Important Points - **Historical Context**: The aviation industry has never faced large-scale supply issues before, with the current situation being unprecedented. The historical context suggests that supply-side reforms can lead to improved stock performance [4]. - **Previous Anti-Involution Success**: The express delivery sector previously experienced a successful anti-involution campaign in 2021, which stabilized prices and improved profitability. The current environment shows similarities, but the competitive landscape has shifted [9][10]. - **Future Projections**: The express delivery sector may see a repeat of past recovery patterns if regulatory measures are effectively implemented and if companies can enhance their core capabilities [9][10].

Core Viewpoint - Dongyangguang Pharmaceutical is on the verge of officially listing on the Hong Kong Stock Exchange after successfully passing the necessary shareholder votes for privatization and merger with its subsidiary Dongyangguang Changjiang Pharmaceutical [1][2]. Group 1: Listing Process - Dongyangguang Pharmaceutical announced its application for listing on June 29, and the final step involves the approval of the privatization and merger proposal, which received over 99% support from shareholders on July 21 [1][2]. - The company will commence trading on the Hong Kong Stock Exchange on August 7, 2023 [2]. Group 2: Merger and Share Exchange - The listing will occur through a unique method of "absorption merger + introduction," marking a first in the Hong Kong market [3]. - The share exchange ratio is set at 0.263614 shares of Dongyangguang Pharmaceutical for each share of Dongyangguang Changjiang Pharmaceutical, with the theoretical value of Dongyangguang Pharmaceutical's H-shares estimated between 67.04 HKD and 81.44 HKD by the end of 2024 [4]. Group 3: Special Dividend and Shareholder Benefits - Shareholders of Dongyangguang Changjiang Pharmaceutical will receive a special dividend of 1.50 HKD per share post-merger, with approximately 4.28 billion H-shares eligible for this dividend [4][6]. - The potential premium for minority shareholders, considering the privatization and special dividend, could exceed 40% since the stock price on June 27 was 14.90 HKD, while the estimated value during privatization is around 19.36 HKD [4][6]. Group 4: Growth Potential and Innovation - Dongyangguang Pharmaceutical has seen a stock price increase of over 70% year-to-date, indicating strong market performance [6]. - The company has developed a comprehensive R&D platform over 20 years, with 150 drugs available globally and over 100 in development, including 49 first-class innovative drugs with significant commercial potential [6][7]. - Notable drugs include Clifofitinib, with a peak sales potential of 1 billion USD, and another drug, Ifenidone, which shows promise in treating various conditions [7].

Group 1 - UBTECH announced its fifth equity financing since its IPO, aiming to raise approximately HKD 24.73 billion by issuing about 30.16 million new H-shares at HKD 82.00 per share, which is a discount of about 9.14% from the closing price on July 21, 2025 [1] - The total amount raised by UBTECH, including the IPO, has reached HKD 55.82 billion, corresponding to approximately 13.85% of the company's total share capital post-financing [1] Group 2 - GoerTek submitted a prospectus to the Hong Kong Stock Exchange for its subsidiary, GoerTek Microelectronics, aiming for a listing on the main board, marking its second attempt after a previous application lapsed on January 20, 2025 [2] - GoerTek Microelectronics holds a 4.3% market share in the global sensor market, ranking fourth, and a 43.0% share in the acoustic sensor market, ranking first [2] Group 3 - Xiechuang Data announced plans for an IPO in Hong Kong to enhance its international strategy and overseas financing capabilities, focusing on IoT smart terminals and data storage devices [3] - The company, which was listed on the Shenzhen Stock Exchange in July 2020, currently has a market capitalization of approximately RMB 27.51 billion [3] Group 4 - Dongyang Sunshine Pharmaceutical's absorption merger plan was approved with over 99% support at a shareholder meeting, marking a significant step in its listing process, with plans to officially list on August 7 [4] - This merger represents the first case of an H-share absorption merger and privatization listing on the Hong Kong Stock Exchange, avoiding new share issuance while achieving asset integration [4] Group 5 - The Hang Seng Index closed at 25,130.03, with a gain of 0.54% on July 22 [5] - The Hang Seng Tech Index and the National Enterprises Index also saw increases of 0.38% and 0.39%, closing at 5,606.83 and 9,075.60 respectively [5]

Key Points - The article discusses various important news and updates related to the investment landscape, including new regulations, market performance, and company announcements. Group 1: Regulatory Updates - The "Housing Rental Regulations" were published, effective from September 15, 2025, aiming to standardize rental activities and enhance supervision of rental enterprises and agencies [3] - The "Cross-Border Asset Management Pilot Business Implementation Rules" set an initial total scale limit of 10 billion RMB for cross-border asset management products, which can be adjusted dynamically based on market conditions [3] Group 2: Market Performance - In June, the total electricity consumption reached 8,670 billion kWh, a year-on-year increase of 5.4%, with significant growth in residential electricity consumption at 10.8% [4] - Hong Kong's IPO market has seen 52 IPOs this year, a 30% increase year-on-year, raising a total of 124 billion HKD, up 590% [4] Group 3: Company Announcements - Dalian Shengya is planning to issue shares to specific investors, which may lead to a change in company control, and will be suspended from trading starting July 22 [7] - Hai Tian Rui Sheng expects a net profit increase of 607.01% to 960.52 million RMB for the first half of the year [8] - Gongde Infrared signed contracts worth 685 million RMB for overseas market orders [8] - Anning Co. plans to acquire 100% equity in three companies for 6.508 billion RMB [8] Group 4: Industry Insights - Guotai Junan highlights that the mechanical industry will face both opportunities and challenges in 2025, with domestic excavator sales expected to continue recovering [8] - Zhongtai Securities remains optimistic about the banking sector's stability and sustainability, projecting a slight recovery in net interest income and overall profitability [9]

Group 1: Market Developments - Hong Kong Stock Exchange will lower the minimum price fluctuation for stocks starting August 4, 2025, following successful market rehearsals and regulatory approvals [1] - The Hang Seng Index's ADR closed at 24,987.99 points, down 6.15 points or 0.02% [3] Group 2: Index Adjustments - The Hang Seng Index announced changes to the calculation method of the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index, effective from the index review on June 30, 2025 [2] Group 3: Company Earnings - Cathay Pacific reported a 23.3% year-on-year increase in passenger numbers, carrying approximately 2.9 million passengers in June 2025 [8] - China Longgong expects a significant increase in net profit for the first half of 2025, estimated between RMB 590 million and RMB 665 million, representing a year-on-year increase of 29% to 45% [11] - Meitu Company anticipates a 65% to 72% year-on-year growth in adjusted net profit for the first half of 2025 [10] - Hengtou Securities expects a net profit of approximately RMB 239 million for the first half of 2025, a significant increase from RMB 53.87 million in the same period last year [14] - Huiri Group forecasts a consolidated profit of approximately HKD 250 million for the first half of 2025, up from HKD 37 million in the previous year [15] - Harbin Electric anticipates a net profit of approximately RMB 1.02 billion for the first half of 2025, a substantial increase from RMB 523 million in the same period last year [21] Group 4: Strategic Initiatives - Multiple departments released implementation details for cross-border asset management pilot business in Hainan Free Trade Port, allowing foreign investors to invest in various financial products [6] - Dongyangguang Jiangsu Pharmaceutical and Dongyangguang Pharmaceutical's merger agreement was approved by shareholders, with the new entity expected to be listed on August 7, 2025 [13] - Global New Materials International's acquisition of Merck's surface solutions business was approved by a special shareholder meeting, with a transaction value of EUR 665 million [17] Group 5: Industry Trends - GGII reported that China's power battery installation capacity reached approximately 288.1 GWh in the first half of 2025, a year-on-year increase of 44% [5] - The key product DB-1310 from InnoCare Pharma has received fast track designation from the FDA for treating advanced non-small cell lung cancer [20]

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

Core Viewpoint - The acquisition of Hangzhou Huacheng Network Technology Co., Ltd. by Zhongwei Capital, in partnership with Chenyi Fund and Tencent, marks a significant move in the global M&A landscape, highlighting the potential for Chinese brands in the global market [2][4]. Group 1: Company Overview - Huacheng Network, incubated by Dahua Technology in 2015, has become a leading global smart home brand, focusing on the consumer IoT market with a product range that includes smart cameras and locks [2]. - The company has developed a comprehensive global sales network, serving over 45 million users and exporting products to over 100 countries, with significant operations in Southeast Asia, Latin America, and Europe [3]. Group 2: Market Position and Growth - According to IDC's report, Huacheng ranks among the top three in global consumer camera shipments, with overseas sales accounting for 77.1% of its total shipments in Q1 2025, indicating strong international growth potential [3]. - The Asia-Pacific region is identified as a strategic focus area for Huacheng, reinforcing its market leadership in that region [3]. Group 3: Investment Strategy - The acquisition represents Zhongwei Capital's first M&A project through its RMB fund, reflecting its commitment to deepening its investment in the consumer technology sector [4]. - Zhongwei Capital has a management scale exceeding RMB 15 billion and has previously engaged in high-profile acquisitions, including the Italian luxury brand Frette and the parent company of Arc'teryx [4]. Group 4: Future Outlook - Zhongwei Capital's partner, Yao Anmin, emphasized Huacheng as a representative of Chinese smart hardware brands, with a focus on enhancing global competitiveness through AI and cloud technology applications [5]. - The company aims to continue supporting Chinese enterprises in their global expansion and is actively seeking high-growth acquisition opportunities [5].